Alvotech (ALVO) Capital Expenditures (2022 - 2026)
Alvotech's (ALVO) quarterly Capital Expenditures came in at -$27.9 million in Q2 2026, down 104.64% on a YoY basis from $600.5 million in Q2 2025, and down 290.2% quarter-over-quarter from -$7.1 million in Q1 2026.
Analysis
Alvotech (ALVO) Capital Expenditures (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Capital Expenditures for 5 consecutive years, with -$27.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Capital Expenditures fell 104.64% year-over-year to -$27.9 million; the trailing twelve-month figure through Jun 2026 stood at -$62.7 million (up 39.9% YoY), and the FY2025 full-year result was -$64.5 million, down 20.14% from the prior year.
- Capital Expenditures slipped to -$27.9 million in Q2 2026 per ALVO's latest filing, from -$7.1 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $19.6 million in Q2 2022 and bottomed at -$53.7 million in Q4 2024.
- Historically, Capital Expenditures has averaged -$17.1 million across 5 years, with a median of -$13.7 million in 2024.
- The widest YoY moves for Capital Expenditures: up 83.71% in 2025, down 469.85% in 2025.
- Over 5 years, Capital Expenditures stood at -$37.9 million in 2022, then climbed by 12.27% to -$33.2 million in 2023, then tumbled by 61.46% to -$53.7 million in 2024, then soared by 83.71% to -$8.7 million in 2025, then slumped by 218.89% to -$27.9 million in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$27.9 million, -$7.1 million, and -$8.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 104.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 52.80 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -36.19 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 30.70 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 77.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -27.87 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 3.05 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 8.59 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.87 Mn |
| Mar 31, 2026 | -7.14 Mn |
| Dec 31, 2025 | -8.74 Mn |
| Sep 30, 2025 | -18.93 Mn |
| Jun 30, 2025 | -13.62 Mn |
| Mar 31, 2025 | -23.19 Mn |
| Dec 31, 2024 | -53.66 Mn |
| Sep 30, 2024 | -13.82 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Dec 31, 2023 | -33.23 Mn |
| Jun 30, 2023 | -11.27 Mn |
| Dec 31, 2022 | -37.88 Mn |
| Jun 30, 2022 | 19.57 Mn |